These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 33890058

  • 1. Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy.
    Grover A, Quaye E, Brychta RJ, Christensen J, Startzell MS, Meehan CA, Valencia A, Marshall B, Chen KY, Brown RJ.
    J Clin Endocrinol Metab; 2021 Sep 27; 106(10):e4163-e4178. PubMed ID: 33890058
    [Abstract] [Full Text] [Related]

  • 2. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ, Valencia A, Startzell M, Cochran E, Walter PJ, Garraffo HM, Cai H, Gharib AM, Ouwerkerk R, Courville AB, Bernstein S, Brychta RJ, Chen KY, Walter M, Auh S, Gorden P.
    J Clin Invest; 2018 Aug 01; 128(8):3504-3516. PubMed ID: 29723161
    [Abstract] [Full Text] [Related]

  • 3. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1511-1519. PubMed ID: 28324110
    [Abstract] [Full Text] [Related]

  • 4. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T, Cochran E, Gorden P, Brown RJ.
    J Clin Endocrinol Metab; 2015 May 01; 100(5):1802-10. PubMed ID: 25734254
    [Abstract] [Full Text] [Related]

  • 5. Leptin Decreases Gluconeogenesis and Gluconeogenic Substrate Availability in Patients With Lipodystrophy.
    Quaye E, Chacko S, Startzell M, Brown RJ.
    J Clin Endocrinol Metab; 2023 Dec 21; 109(1):e209-e215. PubMed ID: 37515588
    [Abstract] [Full Text] [Related]

  • 6. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
    Cook K, Ali O, Akinci B, Foss de Freitas MC, Montenegro RM, Fernandes VO, Gupta D, Lou KJ, Tuttle E, Oral EA, Brown RJ.
    J Clin Endocrinol Metab; 2021 Jul 13; 106(8):e2953-e2967. PubMed ID: 33822100
    [Abstract] [Full Text] [Related]

  • 7. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, Gorden P.
    Endocr Pract; 2011 Jul 13; 17(6):922-32. PubMed ID: 22068254
    [Abstract] [Full Text] [Related]

  • 8. Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides.
    Joseph J, Shamburek RD, Cochran EK, Gorden P, Brown RJ.
    J Clin Endocrinol Metab; 2014 Sep 13; 99(9):E1676-80. PubMed ID: 24926953
    [Abstract] [Full Text] [Related]

  • 9. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G, Akinci B.
    Recent Pat Endocr Metab Immune Drug Discov; 2015 Sep 13; 9(2):74-8. PubMed ID: 26556498
    [Abstract] [Full Text] [Related]

  • 10. Rationale for leptin-replacement therapy for severe lipodystrophy.
    Oral EA, Chan JL.
    Endocr Pract; 2010 Sep 13; 16(2):324-33. PubMed ID: 20061299
    [Abstract] [Full Text] [Related]

  • 11. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
    Nguyen ML, Sachdev V, Burklow TR, Li W, Startzell M, Auh S, Brown RJ.
    J Clin Endocrinol Metab; 2021 Oct 21; 106(11):e4327-e4339. PubMed ID: 34223895
    [Abstract] [Full Text] [Related]

  • 12. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
    Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P.
    Expert Rev Clin Pharmacol; 2016 Oct 21; 9(1):59-68. PubMed ID: 26465174
    [Abstract] [Full Text] [Related]

  • 13. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.
    Christensen JD, Lungu AO, Cochran E, Collins MT, Gafni RI, Reynolds JC, Rother KI, Gorden P, Brown RJ.
    J Clin Endocrinol Metab; 2014 Aug 21; 99(8):E1493-500. PubMed ID: 25070319
    [Abstract] [Full Text] [Related]

  • 14. Metreleptin worked in a diabetic woman with a history of hematopoietic stem cell transplantation (HSCT) during infancy: further support for the concept of 'HSCT-associated lipodystrophy'.
    Adachi M, Muroya K, Hanakawa J, Asakura Y.
    Endocr J; 2021 Apr 28; 68(4):399-407. PubMed ID: 33229817
    [Abstract] [Full Text] [Related]

  • 15. Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy.
    Meral R, Malandrino N, Walter M, Neidert AH, Muniyappa R, Oral EA, Brown RJ.
    J Clin Endocrinol Metab; 2022 Mar 24; 107(4):e1739-e1751. PubMed ID: 34677608
    [Abstract] [Full Text] [Related]

  • 16. Leptin decreases de novo lipogenesis in patients with lipodystrophy.
    Baykal AP, Parks EJ, Shamburek R, Syed-Abdul MM, Chacko S, Cochran E, Startzell M, Gharib AM, Ouwerkerk R, Abd-Elmoniem KZ, Walter PJ, Walter M, Muniyappa R, Chung ST, Brown RJ.
    JCI Insight; 2020 Jul 23; 5(14):. PubMed ID: 32573497
    [Abstract] [Full Text] [Related]

  • 17. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy.
    Miehle K, Stumvoll M, Fasshauer M, Hierl T.
    Endocrine; 2017 Nov 23; 58(2):262-266. PubMed ID: 28993984
    [Abstract] [Full Text] [Related]

  • 18. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
    Nagayama A, Ashida K, Watanabe M, Moritaka K, Sonezaki A, Kitajima Y, Takahashi H, Yoshinobu S, Iwata S, Yasuda J, Hasuzawa N, Ozono S, Motomura S, Nomura M.
    Front Endocrinol (Lausanne); 2021 Nov 23; 12():690996. PubMed ID: 34135866
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
    Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, Brown RJ.
    Clin Endocrinol (Oxf); 2016 Jul 23; 85(1):137-49. PubMed ID: 26589105
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.
    Sekizkardes H, Cochran E, Malandrino N, Garg A, Brown RJ.
    J Clin Endocrinol Metab; 2019 Aug 01; 104(8):3068-3076. PubMed ID: 31194872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.